Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Begelomab - ADIENNE

Next Previous
Drug Profile

Begelomab - ADIENNE

Alternative Names: anti-CD26 begelomab; Begedina; Begesand; BT 5/9; murine anti-CD26 BT 5/9; SAND-26

Latest Information Update: 04 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADIENNE
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dermatomyositis; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Graft-versus-host disease
  • Phase II Dermatomyositis

Most Recent Events

  • 10 Nov 2021 Phase-II clinical trials in Dermatomyositis (Adjunctive treatment, In adults, In the elderly) in Italy (IV) (EudraCT2021-000898-83)
  • 08 Sep 2021 Begelomab is still in phase II/III trials for Graft-versus-host disease in Switzerland and USA (ADIENNE website, September 2021)
  • 14 Mar 2019 Begelomab - ADIENNE receives Orphan Drug status for Graft-versus-host disease in Switzerland (ADIENNE website, March 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top